Bristol Myers Squibb remains focused on its efforts to educate and help others understand the complexities of hematology. Learn more about blood disorders here.
Intended for scientific audiences only.
BMS at ASH 2019
The next frontier in research and development at the American Society of Hematology, December 7-10, 2019.
y combining efforts, Bristol Myers Squibb and Celgene are pioneering innovation within the hematology space and expanding our research efforts into new spaces, including CAR T, one of the next frontiers in cell therapy. Read more on how hematology research may impact the future of care.
Samit, Hirawat, Bristol Myers Squibb’s chief medical officer overseeing the Global Drug Development organization, speaks from the ASH meeting in Orlando..
Learning About Hematology
- Acute Myeloid Leukemia >
- Beta Thalassemia >
- Blood Cancers at a Glance >
- Chronic Lymphocytic Leukemia/Small Lyphocytic Lymphoma (CLL/SLL) >
- Diffuse Large B-cell Lymphoma (DLBCL) >
- Indolent Non-Hodgkin’s Lymphoma >
- Lymphoma at a Glance >
- Myelodysplastic Syndromes (MDS) >
- Myelofibrosis >
- Multiple Myeloma at a Glance >